Literature DB >> 16180936

Clarification of terminology in drug safety.

Jeffrey K Aronson1, Robin E Ferner.   

Abstract

Nomenclature surrounding drug safety needs to be clear and unambiguous, so that patients, prescribers, manufacturers, and regulators can all understand each other. In particular, it needs to make it clear how adverse events and drug therapy are related to one another, how they are best classified, and their frequency, intensity and seriousness. In this article, we therefore discuss and define terms used in the field of drug safety, particularly terms that are sometimes misunderstood or misused, including medicinal product, pharmaceutical formulation, excipient, adverse event (or experience) and adverse drug reaction (or effect). We also discuss terms used to define the seriousness, intensity, and risk of adverse reactions, and their classification. Instead of creating definitions from scratch, as is commonly done, we have taken the novel approach of critically examining definitions that have been proposed or widely used and have formulated new or modified definitions based on a logical appraisal of their merits and demerits. We hope that these definitions will lead to discussion that will allow a corpus of satisfactory definitions to be widely agreed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16180936     DOI: 10.2165/00002018-200528100-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  58 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  Adverse drug reactions. A critical review.

Authors:  F E Karch; L Lasagna
Journal:  JAMA       Date:  1975-12-22       Impact factor: 56.272

Review 3.  Cancer: science and society and the communication of risk.

Authors:  K C Calman
Journal:  BMJ       Date:  1996-09-28

4.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

5.  Use of statistics in the analysis of side effect data from clinical trials of psychoactive agents.

Authors:  J R Assenzo; V S Shu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1982       Impact factor: 5.067

Review 6.  A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force.

Authors:  S G Johansson; J O Hourihane; J Bousquet; C Bruijnzeel-Koomen; S Dreborg; T Haahtela; M L Kowalski; N Mygind; J Ring; P van Cauwenberge; M van Hage-Hamsten; B Wüthrich
Journal:  Allergy       Date:  2001-09       Impact factor: 13.146

7.  An algorithm for the operational assessment of adverse drug reactions. III. Results of tests among clinicians.

Authors:  J M Leventhal; T A Hutchinson; M S Kramer; A R Feinstein
Journal:  JAMA       Date:  1979-11-02       Impact factor: 56.272

8.  Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study.

Authors:  G L Zornberg; H Jick
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

9.  Quantitative relationships between sensitizing dose of DNCB and reactivity in normal subjects.

Authors:  P S Friedmann; C Moss; S Shuster; J M Simpson
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

10.  Normal immune response to hepatitis B vaccine in patients with Down's syndrome. A basis for immunization guidelines.

Authors:  C L Troisi; D A Heiberg; F B Hollinger
Journal:  JAMA       Date:  1985-12-13       Impact factor: 56.272

View more
  69 in total

1.  Selected national pharmacovigilance websites: an analysis of contents.

Authors:  Charlotte I S Barker; John C C Talbot; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-02-01       Impact factor: 5.606

2.  Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 3.  Preventability of drug-related harms - part I: a systematic review.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

4.  A manifesto for clinical pharmacology from principles to practice.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

5.  Risk perception in drug therapy.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

6.  Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.

Authors:  Manfred Hauben; Sebastian Horn; Lester Reich
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Clarification of terminology in medication errors: definitions and classification.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 8.  Methods for causality assessment of adverse drug reactions: a systematic review.

Authors:  Taofikat B Agbabiaka; Jelena Savović; Edzard Ernst
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Extension of points on clarifying terminology in drug safety.

Authors:  Manfred Hauben; Lester Reich; Flic Gabbay
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

10.  Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis.

Authors:  Tejas K Patel; Parvati B Patel
Journal:  Eur J Clin Pharmacol       Date:  2018-03-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.